Home

LAWRENCE A KENYON

CIK 1230484 · Chief Financial Officer · last filed 2026-08-14

LAWRENCE A KENYON is a Chief Financial Officer who has filed 27 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for OTLK, was dated Aug 14, 2026. Across all open-market trades the lifetime net is −$460.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $223.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$223.3K

Companies

6

Total Filings

27

Lifetime Open-Market Net

-$460.8K

Filer Profile

Reported Address
C/O OUTLOOK THERAPEUTICS, INC.
7 CLARKE DRIVE
CRANBURY, NJ 08512
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK Chief Financial Officer 106,956 $0.67 $71.3K $28.4K 4 2026-08-14
Outlook Therapeutics, Inc. (OTLKW) Delisted CEO, Pres, CFO, Treas & Secy 18,926 $0.03 $568 $36.1K 9 2021-04-20
Outlook Therapeutics, Inc. (ONSIW) Delisted CEO, Pres, CFO, Treas & Secy 57,213 — — -$8.8K 2 2018-09-18
Outlook Therapeutics, Inc. (ONSIZ) Delisted CFO and Secretary 67,313 — — -$29.6K 2 2017-12-26
PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted EVP, Chief Financial Officer 14,337 — — -$540.4K 6 2010-08-04
ACEL EVP, CFO and Secretary 12,797 $11.88 $152.0K $53.4K 2 2007-04-12

Recent Filings

27 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-14 OTLK Buy (P) +101,010 $0 EDGAR
2026-07-23 OTLK Grant (A) — $0 EDGAR
2024-09-30 OTLK Buy (P) +5,000 $28.4K EDGAR
2024-03-22 OTLK Grant (A) — $0 EDGAR
2021-04-20 Outlook Therapeutics, Inc. (OTLKW) Delisted Buy (P) +10,000 $18.3K EDGAR
2020-10-05 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) — $0 EDGAR
2020-07-21 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) — $0 EDGAR
2020-03-20 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) — $0 EDGAR
2019-10-15 Outlook Therapeutics, Inc. (OTLKW) Delisted Sell (S) −1,350 -$2.3K EDGAR
2019-09-23 Outlook Therapeutics, Inc. (OTLKW) Delisted Sell (S) −1,350 -$2.3K EDGAR
Showing 1–10 of 27
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.